Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXS Neuraxis, Inc.

Closed 11-15 16:00:00 EST

3.15

-0.12

-3.67%

High3.41	Low3.12	Vol7.84K
Open3.34	D1 Closing3.27	Amplitude8.87%
Mkt Cap21.99M	Tradable Cap9.87M	Total Shares6.98M
T/O25.02K	T/O Rate0.25%	Tradable Shares3.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NRXS","market":"US","secType":"STK","nameCN":"Neuraxis, Inc.","latestPrice":3.15,"timestamp":1731704400000,"preClose":3.27,"halted":0,"volume":7835,"delay":0,"floatShares":3134893,"shares":6980227,"eps":-1.225717,"marketStatus":"Closed","change":-0.12,"latestTime":"11-15 16:00:00 EST","open":3.34,"high":3.41,"low":3.1198,"amount":25020.2167,"amplitude":0.088746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.225717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":5,"adr":0,"listingDate":1691553600000,"exchange":"AMEX","adjPreClose":3.27,"volumeRatio":0.174025},"requestUrl":"/m/hq/s/NRXS/tweets","defaultTab":"tweets","newsList":[{"id":"2483585798","title":"NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2483585798","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483585798?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:46","pubTimestamp":1731689160,"startTime":"0","endTime":"0","summary":"Shares of NeurAxis, Inc. NRXS have gained 41.2% since it reported earnings for the quarter ended Sept. 30, 2024. This strong performance contrasts with the S&P 500 index, which saw a decline of 0.9% during the same period. Over the past month, NeurAxis stock has risen 17.7%, outperforming the S&P 500’s 2.1% gain.NeurAxis reported revenues of $0.7 million in third-quarter 2024, marking a 39.6% increase from $0.5 million in third-quarter 2023. Gross profit grew 38.9% year over year to $0.6 million. Gross margin saw a slight decline of 50 basis points from 85.9% in third-quarter 2023 to 85.4% in the reported quarter. This is due to higher growth in the company’s financial assistance programs that are discounted to patients without insurance coverage compared to the company’s undiscounted full reimbursement customers. Operating loss improved significantly to $1.7 million in third-quarter 2024 from $3 million in third-quarter 2023.Revenue growth in third-quarter 2024 was attributed to volum","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4lmvToGK4d2FNc0SIOXMvw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/51f0c2cd09522c9a15cba48260e4facf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4lmvToGK4d2FNc0SIOXMvw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/51f0c2cd09522c9a15cba48260e4facf"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-stock-surges-strong-q3-164600573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXS"],"gpt_icon":0},{"id":"2483435180","title":"NeurAxis Reports Strong Revenue Growth in Q3 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483435180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483435180?lang=en_us&edition=fundamental","pubTime":"2024-11-13 12:52","pubTimestamp":1731473543,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. ( ($NRXS) ) has released its Q3 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors. NeurAxis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-reports-strong-revenue-growth-in-q3-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-reports-strong-revenue-growth-in-q3-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2482701755","title":"Neuraxis Q3 Sales $666.63K Up From $477.46K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2482701755","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482701755?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:16","pubTimestamp":1731417401,"startTime":"0","endTime":"0","summary":"Neuraxis (AMEX:NRXS) reported $666.63 thousand in sales this quarter. This is a 39.62 percent increase over sales of $477.46 thousand the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41899418/neuraxis-q3-sales-666-63k-up-from-477-46k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neuraxis Q3 Sales $666.63K Up From $477.46K YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2482370209","title":"Neuraxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2482370209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482370209?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:10","pubTimestamp":1731417000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUAKBWFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2482631701","title":"Press Release: NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2482631701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482631701?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:10","pubTimestamp":1731417000,"startTime":"0","endTime":"0","summary":"Conference call will be held today, Tuesday, November 12 at 9:00 am ET. CARMEL, Ind., Nov. 12, 2024  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2024.-- Revenues increased 40% to $667 thousand in the three months ended. September 30, 2024  compared to $477 thousand in the three. -- Operating loss improved by 45% compared to the 3Q2023.-- Expanded total covered lives to approximately 35 million compared to 4.5. -- BCBS plan in the mid-Atlantic region, providing coverage for. -- BCBS plan in the mid-Atlantic with approximately 3.5 million. -- One of the nation's largest not for profit health plans, serving over 12. million members, is now providing their members with access to PENFS. -- Received new FDA clearance for the expansion of IB-Stim label:. -- Submitted to the FDA its innovative rectal expulsion d","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2481533854","title":"NeurAxis' IB-Stim Nerve Stimulator for Abdominal Pain Relief Gets New FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2481533854","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481533854?lang=en_us&edition=fundamental","pubTime":"2024-11-05 00:04","pubTimestamp":1730736273,"startTime":"0","endTime":"0","summary":"NeurAxis  said Monday it received a new 510 clearance from the US Food and Drug Administration for its IB-Stim nerve stimulator for functional abdominal pain relief, expanding its indication for use in people between 8 and 21 years of age from a previous indication for 11- to 18-year olds.IB-Stim is a non-surgical device that sends \"gentle\" electrical impulses into cranial nerve bundles in the ear, the medical technology company said.Price: 2.26, Change: -0.33, Percent Change: -12.74","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2480970585","title":"Neuraxis Inc - New Cpt Category I Code Effective January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2480970585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480970585?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:00","pubTimestamp":1730728800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA5DCCJZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2480958597","title":"Neuraxis Receives New FDA 510(K) Clearance for Ib-Stim, Expanding Its Addressable Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2480958597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480958597?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:00","pubTimestamp":1730728800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA5DCCJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2479540769","title":"Neuraxis announces Capital Blue Cross Medical Policy Coverage for PENFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2479540769","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479540769?lang=en_us&edition=fundamental","pubTime":"2024-10-29 21:05","pubTimestamp":1730207122,"startTime":"0","endTime":"0","summary":"NeurAxis (NRXS) announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation, PENFS, for Capital Blue Cross Medical Member...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-announces-capital-blue-cross-medical-policy-coverage-for-penfs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-announces-capital-blue-cross-medical-policy-coverage-for-penfs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2479006402","title":"NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479006402","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479006402?lang=en_us&edition=fundamental","pubTime":"2024-10-29 21:00","pubTimestamp":1730206800,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Oct. 29, 2024  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation , for Capital Blue Cross Medical Members, effective October 1, 2024. Capital Blue Cross serves a 21-county region in Central Pennsylvania and the Lehigh Valley.NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome  in adolescents 11-18 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Pharmacologic treatments which use drugs off-label can often have serious side effects, and most lack scientific evidence of efficacy.Forward-Looking Statemen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-announces-capital-blue-cross-130000364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2474746237","title":"Amex Halt  Add Info Lst 3.040000","url":"https://stock-news.laohu8.com/highlight/detail?id=2474746237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474746237?lang=en_us&edition=fundamental","pubTime":"2024-10-10 21:42","pubTimestamp":1728567744,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nAQN2JKX03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2474485226","title":"Amex Halt  Add Info Lst 3.040000","url":"https://stock-news.laohu8.com/highlight/detail?id=2474485226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474485226?lang=en_us&edition=fundamental","pubTime":"2024-10-09 22:02","pubTimestamp":1728482530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241009:nAQN2JKP8W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2470298599","title":"Zacks Initiates Coverage of NeurAxis With Neutral Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2470298599","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470298599?lang=en_us&edition=fundamental","pubTime":"2024-09-25 22:49","pubTimestamp":1727275740,"startTime":"0","endTime":"0","summary":"Zacks Investment Research has recently initiated coverage of NeurAxis, Inc. NRXS, assigning a \"Neutral\" recommendation to the company's shares. This assessment comes amid a mixed outlook for the company, which has been making notable strides in the neuromodulation therapies space despite industry challenges.NRXS, headquartered in Carmel, IN, specializes in developing neuromodulation therapies to address chronic conditions, particularly in pediatric populations. NeurAxis' flagship product, the IB-Stim, is a non-surgical, FDA-cleared device designed for treating functional abdominal pain associated with irritable bowel syndrome in adolescents aged 11-18 years.NeurAxis reported a 16% year-over-year increase in unit sales in the second quarter of 2024, alongside securing $9.1 million in funding, which strengthens its financial position. The company’s coverage has surged from 4.5 million lives in May 2023 to approximately 22.5 million in June 2024, with expectations to exceed 50 million by ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.gb6XNijFKw.G0R_D0zzsw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.gb6XNijFKw.G0R_D0zzsw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-initiates-coverage-neuraxis-neutral-144900094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXS"],"gpt_icon":0},{"id":"2470679264","title":"The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2470679264","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470679264?lang=en_us&edition=fundamental","pubTime":"2024-09-25 21:41","pubTimestamp":1727271660,"startTime":"0","endTime":"0","summary":"Chicago, IL – September 25, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Costco Wholesale Corp. COST, Alibaba Group Holding Ltd. BABA, GE Aerospace GE, Applied Energetics, Inc. AERG and NeurAxis, Inc. NRXS.Top Analyst Results for Costco, Alibaba and GE Aerospace","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uzmjcPxILC9RffYKRmYFTw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e563146860145ca5b34d292d38975c7c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uzmjcPxILC9RffYKRmYFTw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e563146860145ca5b34d292d38975c7c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-costco-134100861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4587","COST","BK4524","BK4588","IE00B0JY6N72.USD","LU0918141887.USD","LU2210149790.SGD","LU1496350171.SGD","LU0651946864.USD","BK4187","LU1051768304.USD","LU1069344957.HKD","LU2360106947.USD","LU0471298694.HKD","LU1880383366.USD","LU0918141705.HKD","LU0067412154.USD","BK4526","LU0354030511.USD","BK4581","IE00BZ1G4Q59.USD","LU0310800965.SGD","LU1515016050.SGD","LU2210150020.SGD","LU1035775433.USD","LU2756315664.SGD","LU0868494617.USD","AERG","LU1823568750.SGD","BABA","GE","LU0251143458.SGD","LU1105468828.SGD","NRXS","LU0417517546.SGD","BK4533","LU0471298777.SGD","LU0797268264.HKD","LU0501845795.SGD","LU0880133367.SGD","BK4585","LU0820561818.USD","LU1093756168.USD","LU0820562030.AUD","BK4527","BK4206","09988","BK4082","BK4122","LU0072913022.USD"],"gpt_icon":1},{"id":"2470425361","title":"Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace","url":"https://stock-news.laohu8.com/highlight/detail?id=2470425361","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470425361?lang=en_us&edition=fundamental","pubTime":"2024-09-25 04:30","pubTimestamp":1727209800,"startTime":"0","endTime":"0","summary":"Tuesday, September 24, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco Who","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eTtzIoI2KG2S6UeptMANxA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7908fc2e91430e89c9fb516c3ac4654c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eTtzIoI2KG2S6UeptMANxA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7908fc2e91430e89c9fb516c3ac4654c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-costco-wholesale-203000832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B0JY6N72.USD","LU0067412154.USD","LU0354030511.USD","KNX","LU1551013342.USD","AMT","LU2065731478.USD","GD","LU0079474960.USD","LU0354030438.USD","LU1169589451.USD","BK4565","BABA","BK4534","LU1823568750.SGD","BK4566","BK4206","GEHC","DKS","VERX","GE","BK4232","BK4585","AERG","MET","LU1280957306.USD","LU1551013425.SGD","LU0310800965.SGD","LU2264538146.SGD","LU2456880835.USD","LU1169590202.USD","NRXS","MTDR","COST","IE00B19Z3B42.SGD","WAB","LU0471298694.HKD","VRTX","LU0501845795.SGD","BK4567","ACV","LU0149725797.USD","IE00BJT1NW94.SGD","LU1066053197.SGD","IE00BFMHRM44.USD","VEEV","AIT","IE0034235188.USD","09988"],"gpt_icon":1},{"id":"2468782574","title":"NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2468782574","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468782574?lang=en_us&edition=fundamental","pubTime":"2024-09-19 21:00","pubTimestamp":1726750800,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Sept. 19, 2024  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-participate-lytham-partners-fall-130000095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2462167228","title":"Neuraxis Announces Geisinger Health Plan Medical Policy Coverage for Penfs, Effective September 15 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2462167228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462167228?lang=en_us&edition=fundamental","pubTime":"2024-08-27 21:01","pubTimestamp":1724763714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240827:nFWN3KE0IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2462604441","title":"NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2462604441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462604441?lang=en_us&edition=fundamental","pubTime":"2024-08-27 21:00","pubTimestamp":1724763600,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Aug. 27, 2024  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation , for Geisinger Health Plan, serving 600,000+ enrollees in central Pennsylvania. This medical policy will bring our national total coverage for PENFS to roughly 24 million insured lives, with more decisions from major payers still pending.Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-announces-geisinger-health-plan-130000756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2459906164","title":"NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2459906164","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459906164?lang=en_us&edition=fundamental","pubTime":"2024-08-13 21:00","pubTimestamp":1723554000,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Aug. 13, 2024  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation , for Blue Cross Blue Shield  of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s b","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-announces-bcbs-vermont-medical-130000269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2458056207","title":"Neuraxis Q2 EPS $(0.42) Up From $(1.21) YoY, Sales $611.50K Down From $646.02K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2458056207","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458056207?lang=en_us&edition=fundamental","pubTime":"2024-08-09 20:18","pubTimestamp":1723205910,"startTime":"0","endTime":"0","summary":"Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.42) per share. This is a 65.29 percent increase over losses of $(1.21) per share from the same period last year.  The company reported $611.50 thousand in sales this","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40282294/neuraxis-q2-eps-0-42-up-from-1-21-yoy-sales-611-50k-down-from-646-02k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neuraxis Q2 EPS $(0.42) Up From $(1.21) YoY, Sales $611.50K Down From $646.02K YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.308},{"period":"1month","weight":0.1276},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0757},{"period":"1year","weight":0.1934},{"period":"ytd","weight":0.2247}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. NeurAxis, Inc. was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is based in Versailles, Indiana.","exchange":"AMEX","name":"Neuraxis, Inc.","nameEN":"Neuraxis, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neuraxis, Inc.(NRXS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neuraxis, Inc.,NRXS,Neuraxis, Inc.股票,Neuraxis, Inc.股票老虎,Neuraxis, Inc.股票老虎国际,Neuraxis, Inc.行情,Neuraxis, Inc.股票行情,Neuraxis, Inc.股价,Neuraxis, Inc.股市,Neuraxis, Inc.股票价格,Neuraxis, Inc.股票交易,Neuraxis, Inc.股票购买,Neuraxis, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neuraxis, Inc.(NRXS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction